Esra Aslan, Serhat Yildizhan, Mehmet Bilgehan Pektas, Fatma Firat, Cigdem Karaca

Suppressive effects of resveratrol on epithelial-mesenchymal transition in the YKG1 glioblastoma cell-line

Glioblastoma multiforme (GBM), is an aggressive tumor type with high mortality and morbidity, which a curative treatment method has not been developed yet. Although Epithelial-mesenchymal transition (EMT) is a known mechanism to be effective in the cancer process, the EMT process seen in these cells has not been fully explained yet. Resveratrol is a flavonoid and has been reported to have positive effects on different types of cancer. In this study, we aimed to compare the effects of resveratrol on EMT in YKG1 GBM cell line. Different doses of resveratrol (50 and 100 μM) were applied to YKG1 glioblastoma cells, and their viability was calculated and immunocytochemical analyzes were evaluated. According to results, it was observed that the 100 μM resveratrol dose significantly reduced the viability compared to the 50 μM resveratrol dose. It was determined that Vimentin and N-Cadherin H scores of 100 μM Resveratrol dose decreased and E-cadherin and Claudin-1 values increased compared to the other groups. The results showed that increasing resveratrol dose was more effective on EMT on glioblastoma cell lines in a dose-dependent manner.

PDF

___

1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016;131:803-20.
2. Tan AC, Ashley DM, López GY, et al. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020;70:299-312.
3. Lee KH, Ahn EJ, Oh SJ, et al. KITENIN promotes glioma invasiveness and progression, associated with the induction of EMT and stemness markers. Oncotarget. 2015;6:3240-53.
4. Song Y, Chen Y, Li Y, et al. Resveratrol suppresses epithelial-mesenchymal transition in GBM by regulating smad-dependent signaling. Biomed Res Int. 2019;2019:1321973.
5. Dongre A, Weinberg RA. New insights into the mechanisms of epithelialmesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69-84.
6. Yang J, Antin P, Berx G, et al. Guidelines and definitions for research on epithelial–mesenchymal transition. Rev Mol Cell Biol. 2020;21:341-52.
7. Babaei G, Aziz SG-G, Jaghi NZZ. EMT, cancer stem cells and autophagy; The three main axes of metastasis. Biomed Pharmacother. 2020;133:110909. 8. Ko J-H, Sethi G, Um J-Y, et al. The role of resveratrol in cancer therapy. Int J Mol Sci. 2017;18:2589.
9. Pektas MB, Yucel G, Koca HB, et al. Dietary fructose-induced hepatic injury in male and female rats: Influence of resveratrol. Drug Res. 2017;67:103- 10.
10. Bozkurt E, Pektas G. The regulatory effects of resveratrol on the expression of renal MMP-2 and MMP-9 in the rat models of diabetes. Ant J Bot. 2020;4:85-91.
11. Pektas A, Sadi G, Pektas MB, et al. Effects of resveratrol on diabetes induced vascular tissue damage and inflammation in male rats. Turk J Biochem. 2016;42:451–8.
12. Pektas MK, Pektas MB, et al. Can resveratrol supplementation reduce adverse effects of metabolic syndrome on ovaries? Turkish Clin J Gynecol Obst. 2014;24:98-103.
13. Pektas G, Aslan E, Guzel H, et al. Effects of resveratrol and 1,3-bis(2- chloroethyl)-1-nitrosurea combination on YKG1 glioblastoma cells. Ant J Bot. 5:51-7.
14. Carter LG, D'Orazio JA, Pearson KJ. Resveratrol and cancer: Focus on in vivo evidence. Endocr Relat Cancer. 2014;21:209-25.
15. Bozkurt E, Atay E, Pektas G, et al. Potential anti-tumor activity of kefirinduced juglone and resveratrol fractions against Ehrlich ascites carcinomabearing BALB/c mice. Iranian J Pharm Res. 2020;19:358-69.
16. Sahin Z, et al. Distribution of Notch Family Proteins in Intrauterine Growth Restriction and Hypertension Complicated Human Term Placentas. Acta Histochem. 2011;113:270–6.
17. Ziberi S, Zuccarini M, Carluccio M, et al. Upregulation of epithelial-tomesenchymal transition markers and P2X7 receptors is associated to increased invasiveness caused by P2X7 receptor stimulation in human glioblastoma stem cells. Cells. 2019;9:85.
18. Mahabir R, Tanino M, Elmansuri A, et al. Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma. Neuro Oncol. 2014;16:671-85.
19. Kahlert UD, Nikkhah G, Maciaczyk J. Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas. Cancer Lett. 2013;331:131-8.
20. Jolly MK, Tripathi SC, Jia D, et al. Stability of the hybrid epithelial/ mesenchymal phenotype. Oncotarget. 2016;7:27067-84.
21. Iser IC, Pereira MB, Lenz G, et al. The epithelial-to-mesenchymal transition-like process in glioblastoma: An updated systematic review and in silico investigation. Med Res Rev. 2017;37:271-313.
22. Ozbalci FI, Kacaroglu D, Gurbuz N. Extracellular matrix degradation targeted therapy approachesin pancreatic ductal adenocarcinoma. SDU J Health Science. 2020;11:260-5.
23. Cilibrasi C, Riva G, Romano G, et al. Resveratrol impairs glioma stem cells proliferation and motility by modulating the wnt signaling pathway. PLoS One. 2017;12:e0169854.
24. Lin L, Wang G, Ming J, et al. Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients. Tumor Biol. 2016;37:15333-9.
25. Zhao J, Zhang L, Dong X, et al. High expression of vimentin is associated with progression and a poor outcome in glioblastoma. Appl Immunohistochem Mol Morphol. 2018;26:337-44.
26. Nowicki MO, Hayes JL, Chiocca EA, et al. Proteomic analysis implicates vimentin in glioblastoma cell migration. Cancers. 2019;11:466.
27. Kang YH, Han SR, Jeon H, et al. Nogo receptor–vimentin interaction: A novel mechanism for the invasive activity of glioblastoma multiforme. Exp Mol Med. 2019;51:1-15.
28. Gheldof A, Berx G. Cadherins and epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci. .2013;116:317-36.
29. Han S-P, Kim J-H, Han M-E, et al. SNAI1 is involved in the proliferation and migration of glioblastoma cells. Cell Mol Neurobiol. 2011;31:489-96.
30. Yuan FL, Sun ZL, Feng Y, et al. Epithelial–mesenchymal transition in the formation of hypertrophic scars and keloids. J Cell Physiol. 2019;